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Available online 2 October 2016Cognitive behavioural therapy (CBT) is an effective treatment for health anxiety, but more research is needed to
evaluate accessible, low cost ways of delivering CBT. Internet CBT may be effective, but there are no iCBT pro-
grams available outside of Sweden. We developed the ﬁrst English-language clinician-guided iCBT program for
health anxiety and conducted an open pilot trial (n=16) to examine its acceptability, and impact on health anx-
iety and comorbidity, disability, and the cognitive and behavioural factors thought to maintain the disorder
(e.g., catastrophising, hypervigilance). 13/16 participants completed the program (81% adherence). We found
large and signiﬁcant reductions in health anxiety, depression, distress, anxiety and disability (g's N 1.0), dysfunc-
tional cognitions, behaviours and body vigilance between pre- and post-treatment, whichweremaintained at 3-
month follow-up. The results provide preliminary support for the use of iCBT for health anxiety. Randomised con-
trolled efﬁcacy trials are now needed to evaluate this program.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Health anxiety
Illness anxiety disorder
Cognitive behavioural therapy
Anxiety
Illness
Treatment outcome1. Introduction
Health anxiety is a disabling condition characterised by excessive
fears of having or developing serious illnesses, misinterpretation of
bodily symptoms and body hypervigilance, andmaladaptive behaviours
including body checking and excessive reassurance-seeking, (Fink et al.,
2010). Health anxiety is a core feature of the new Illness Anxiety Disor-
der (IAD) and Somatic Symptom Disorder (SSD) diagnoses in DSM-5
(American Psychiatric Association, 2013), but is less restrictive and
more clinically useful ‘diagnosis’ compared to the narrowly deﬁned
DSM-5 IAD criteria, which excludes individualswho experience somatic
symptoms (Tyrer et al., 2016).
Epidemiological studies suggest that health anxiety is common in
the community, with prevalence estimates ranging between 3.4%
(Sunderland et al., 2012) and 7.7% (Creed and Barsky, 2004;
Sunderland et al., 2013). Health anxiety is associatedwith a range of ad-
verse consequences including high distress, poor occupational function-
ing, days out of role, and loss of quality of life, higher physical disability
and greater rates of comorbid mental and physical disorders, and poor
interpersonal relationships including the strained relationships with
doctors (Conradt et al., 2006; Gureje et al., 1997; Sunderland et al.,
2012). Health anxiety is also a key driver of health service use and linkedMathews Building, University of
. This is an open access article underto high health care utilisation (Bobevski et al., 2016; Fink et al., 2010),
and characterises patients who persistently and frequently attend pri-
mary care (Patel et al., 2015).
Cognitive Behavioural Therapy (CBT) has been shown to be effective
for treating health anxiety (Thomson and Page, 2007), and is preferred
overmedications (Walker et al., 1999). CBT is based on cognitive behav-
ioural models of health anxiety (Warwick, 1989; Warwick and
Salkovskis, 1990) and uses techniques such as cognitive challenging, be-
havioural experiments and graded exposure to modify the cognitive
(e.g., dysfunctional illness beliefs, and catastrophic misinterpretations
of bodily symptoms), emotional (e.g., anxiety and depressed mood)
and behavioural (e.g., reassurance-seeking, checking and avoidance)
variables that are theorised to maintain health anxiety. CBT has been
shown to be effective for patients with elevated health anxiety (Tyrer
et al., 2013) and DSM-IV Hypochondriasis (Seivewright et al., 2008;
Sorensen et al., 2011; Warwick et al., 1996). A recent meta-analysis of
13 randomised controlled trials (RCTs) of CBT interventions for health
anxiety (Olatunji et al., 2014) found large between-groups differences
between CBT and control conditions at post-treatment (mean g =
0.95) and follow-up (mean g= 0.35).
Although CBT is an established evidence-based treatment for health
anxiety, it can be difﬁcult to access and expensive to deliver (Seivewright
et al., 2008). Because patients with health anxiety typically attribute their
symptoms to medical rather than psychological causes, they tend to pres-
ent to medical settings or medical health services (e.g., GPs, emergency,
outpatient medical clinics) rather than psychological services. Referral to
psychiatrists or psychologists can be fraught and difﬁcult. It is now athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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anxiety in a manner deemed acceptable to the patient.
One approach which has seen recent success is the use of the inter-
net to deliver CBT. iCBT is low-cost, highly scalable and convenient, and
private, and can be prescribed and supervised within general and med-
ical practice (Newby et al., 2014). iCBT is effective for the treatment of a
range of anxiety disorders, depression, and somatic conditions including
irritable bowel syndrome (IBS), and chronic pain (Andrews et al., 2010;
Hedman et al., 2012). Hedman and colleagues found that 12-weeks of
therapist-supported iCBT was more effective than an online discussion
forum control group in reducing health anxiety, and comorbid anxiety
and depression (ds = 1.05–1.62), with gains maintained at 6-month
and 12-month follow-up (see Hedman et al., 2013a, 2013b, and 2013c
for 12-month outcomes). In a secondRCT, Hedman et al. (2014) showed
that iCBTwas signiﬁcantlymore effective than an internet-delivered be-
havioural stress management (iBSM) program in reducing health anxi-
ety at post-treatment, although both treatment groups showed large
pre- to post-treatment improvements (iCBT: d = 1.78; iBSM d =
1.22). A recent RCT with participants with DSM-5 diagnoses of IAD or
SSD conducted by Hedman et al. found that both guided iCBT and un-
guided iCBT demonstrated large effects sizes in reducing health anxiety,
with beneﬁts observedwith limited therapist contact time (M=64min
in the guided condition) (Hedman et al., 2016). Together, these studies
demonstrate that iCBT for either hypochondriasis or health anxiety is
feasible and effective in reducing health anxiety symptoms. However,
to our knowledge there are no existing programs for the online treat-
ment of health anxiety outside of Sweden, and iCBT for health anxiety
has never been evaluated by a research team independent from
Hedman's research team.
To address this gap, we developed a new online 6-lesson English-
language CBT program for health anxiety (the Health Anxiety Pro-
gram), and evaluated the feasibility and acceptability of the program
in a small open pilot trial with participants who met DSM-5 criteria
for either Illness Anxiety Disorder (IAD) or Somatic Symptom Disor-
der (SSD). We included participants with either IAD or SSD (rather
than restricting our inclusion criteria to IAD only) because the new
overly restrictive DSM-5 IAD criteria would exclude individuals
with moderate to severe somatic symptoms, which is a common
and deﬁning feature of health anxious individuals. This is the ﬁrst
time iCBT for health anxiety has been evaluated by a research
group independent fromHedman's research team. The iCBT program
was modelled on existing research-tested iCBT programs developed
and evaluated by our team (Mahoney et al., 2014; Newby et al., 2013;
Perini et al., 2009), and comprised evidence-based CBT techniques
drawn from existing CBT treatment protocols for health anxiety
(Abramowitz and Braddock, 2011; Furer et al., 2007) and self-help
texts (Anderson et al., 2011).
Our ﬁrst aim was to assess the impact of the iCBT program on
health anxiety, comorbid symptoms (depression, distress, and gen-
eralised anxiety), functional impairment, as well as the cognitive
(e.g., hypervigilance, dysfunctional cognitions about health and ill-
ness, intolerance of uncertainty, mindful awareness) and behaviour-
al (e.g., avoidance and safety behaviours such as checking and
reassurance-seeking) processes that the iCBT program was designed
to target. Our second aimwas to explore the acceptability of this pro-
gram, which we evaluated through adherence/completion rates, and
patient satisfaction ratings. Because of the tendency for health anx-
ious individuals to become overly anxious and amplify somatic
symptoms when reading information about health and health con-
cerns (Barsky et al., 1990; Ferguson et al., 2000), we also assessed
whether any participants reported negative emotional reactions to
the lessons, and/or unwanted side effects from participating in the
program. In line with previous studies we expected large reductions
in health anxiety and comorbid symptoms of depression and anxiety,
good adherence (N70%) and that participants would ﬁnd the pro-
gram acceptable.2. Method
2.1. Design
An open pilot trial design was used to explore the effects of the iCBT
program. Participants were assessed at pre-, mid-treatment, post-
treatment and at 3 months post-treatment.
2.2. Inclusion/exclusion criteria
Inclusion criteria were: (i) aged over 18, (ii) self-identiﬁed as
experiencing symptoms of health anxiety and met criteria for a diagno-
sis of either DSM-5 IAD or SSD according to structured telephone diag-
nostic interview (if the participant met criteria for SSD, they must
have endorsed criterion B2 of the DSM-5 criteria indicating the experi-
ence of persistently high level of anxiety about health or symptoms),
(iii) prepared to provide their name, phone number and address, and
the name and address of their local general practitioner, (iv) had
attended a general practitioner for assessment of their physical health
over thepast 6months, (v) had access to a phone, computer and printer,
(vi) if taking antidepressant medications, were on a stable dose in the 2
months prior to assessment, and (vi) had not started psychological ther-
apy in the2months prior to assessment. Exclusion criteria included psy-
chosis or bipolar disorder, drug or alcohol dependence, current
suicidality, current use of antipsychotic or regular benzodiazepinemed-
ications, or severe depression (PHQ-9 total scores N24).
2.3. Procedure
Participants applied online to www.virtualclinic.org.au after reading
details about the study. The online screening assessment comprised de-
mographic questions, the Short Health Anxiety Inventory (Salkovskis
et al., 2002) to assess health anxiety severity, the Patient Health Ques-
tionnaire (PHQ-9) (Kroenke et al., 2001) to assess depression severity
and suicidal ideation. Participants who met online screening criteria
then participated in a brief phone interviewwith a trained Clinical Psy-
chologist with a PhD qualiﬁcation in Clinical Psychology. The interview-
er administered a structured diagnostic interview that consisted of an
abbreviated version of the Anxiety Disorders Interview Schedule
(ADIS-5) to conﬁrm whether the applicant met DSM-5 criteria for IAD
or SSD, supplemented with the modules from the Mini International
Neuropsychiatric Interview Version 5.0.0 (Sheehan et al., 1998) to as-
sess for the presence of current comorbid Panic Disorder, Agoraphobia,
Generalised Anxiety Disorder (GAD), Obsessive Compulsive Disorder
(OCD) and Major Depressive Disorder (MDD).
2.4. Participant ﬂow
Details of participant ﬂow are provided in Fig. 1. A total of 87 appli-
cants applied to the programbetween 2March 2015, and 10 April 2015.
Of these, 57 applicants were excluded at online application, and a fur-
ther 11were excluded at the telephone interview, leaving 19 applicants
whomet inclusion criteria. Of these, two did not provide informed con-
sent; one participant did not start the program (and had provided no
baseline data). This left 16 participants who started the Health Anxiety
Program, had baseline data and were included in the analysis. Data
were collected from 14/16 participants at post-treatment, and 12/
16 at follow-up. The studywas approved by the Human Research Ethics
Committee (HREC) of St Vincent's Hospital (Sydney, Australia) (HREC/
14/SVH/294), and the trial was registered with the Australian and
New Zealand Clinical Trials Registry (ACTRN1261500033856).
2.5. Treatment program
The Health Anxiety Program consisted of 6 online lessons completed
over 10 weeks, and was delivered via www.virtualclinic.org.au. The
17 participants were allocated to iCBT 
Unsuccessful Application (n=57)  
• Incomplete Application (n=44)
• No access to internet/computer (n=3) 
• Bipolar or Psychotic Disorder (n=1) 
• Taking exclusion criteria medications (n=5) 
• Suicidal ideation/history of suicidality (n =4) 
30 individuals met inclusion criteria and proceeded to telephone interview with ADIS-5 
87 individuals applied to the iCBT Program within timeframe (2 March-10 April 2015) 
Unsuccessful Diagnostic Interview (n=13) 
• Could not contact (n=6) 
• Does not meet diagnostic criteria for IAD/SSD (n=1) 
• Recent commencement of psychotherapy (n=1) 
• Decide not to proceed (n=2) 
• Did not provide consent (n=2) 
• Family member became ill (n=1) 
16 completed Pre-Treatment Questionnaires 
n=1 did not complete baseline questionnaires 
13/16 participants completed all lessons (81.25% 
completion) 
14/16 completed Post-t Questionnaires  
12/16 completed 3 month Follow-Up Questionnaires 
Withdrew (n=1)  
n=1 sought face-to-face treatment  
Eligible for analysis (started lesson 1) n =16  
Fig. 1. Participant ﬂow diagram.
73J.M. Newby et al. / Internet Interventions 6 (2016) 71–79course content is presented in Table 1. In each lesson, participants read
an illustrated story of aﬁctional personwith health anxietywho learned
how tomanage his symptoms using CBT skills. Each lesson also involves
a downloadable lesson summary with recommended homework exer-
cises and tasks. The course also includes a number of downloadable ad-
ditional resources (see Table 1). All participants were sent a CD via post
with the mindfulness of body sensations audio recording to listen to as
part of the lesson 2 homework practice.
2.6. Clinician contact
All participants completing the iCBT course received email and/or
phone contact with the clinician during the treatment period (JN, aPhD-level Clinical Psychologist). All participants were contacted after
lessons 1 and 2 either by email or phone call to encourage their progress
throughout the course and to answer any questions they had about the
program. After lesson 2, we employed a ﬂexible approach to clinician
contact, which was largely dependent on participants needs. Clinician
contact occurred if either the participant initiated it (e.g., they sent an
email asking questions about the program materials), if there was any
evidence of deterioration on the K-10 (a rise in distress between lessons
of 0.5SD or more), or little change in health anxiety scores between
lessons (suggesting lack of improvement). In addition, the clinician
contacted participants if they fell behind on lesson completion dates.
Feedback on homework assignments was not routinely provided.
Time spent contacting the participant (including telephone contact)
Table 1
Lesson content and homework activities in the Health Anxiety Program.
Lesson title Lesson content Homework activities
1 Understanding health
anxiety
• Psychoeducation about health anxiety
• Goal setting using the SMART principle
• The Health Anxiety cycle
• Identifying physiological, cognitive and behavioural symptoms of
health anxiety
• Psychoeducation about the ﬁght or ﬂight response
• Understanding how cognitive behaviour therapy (CBT) can help
• Set goals for treatment
• Complete my own health anxiety cycle
2 Reducing your focus on
health worries, and starting
to reclaim your life
• The noisy body, false alarms and explanations for physical sensations
• The role of attention and attention focus experiment
• Strategies to take the focus off your worries and your bodily sensations:
○ Shifting attention
○ Activity planning
○ Worry-free zones
○ Mindfulness
• Reducing checking and internet searching
• Activity planning
• Bringing mindfulness into each day
• Mindfulness of body sensations exercise
• Checking prevention plan
3 Becoming aware of your
anxious thinking
• Education about the cognitive model and unhelpful thinking errors
• Alternative explanations for physical symptoms
• Thought monitoring
• Thinking about alternative explanations for physical symptoms
• Continue skills from previous lessons (activity planning, mindfulness
of body sensations, worry-free zones, and cutting down checking
and internet searching)
4 Putting your thoughts and
fears to the test
• Thought challenging
• Behavioural experiments (health anxiety experiments)
• Thought challenging
• Behavioural experiments
5 Tackling avoidance and
safety behaviours
• Education about avoidance and safety behaviours
• Graded exposure
• Tolerating uncertainty and doubt
• Create your own exposure stepladder
• Graded exposure
6 Learning how to stay well in
the long-term
• Evaluating progress
• Overview/summary of skills
• Lapses versus relapses
• Relapse prevention plan
Relapse prevention plan
Extra resources:
Boosting motivation, controlled breathing, good sleep guide, helping
your doctor help you, in case of emergency, information for family and
friends, medications, panic attacks, progressive muscle relaxation,
tackling low mood and keeping active, 100 things to do (pleasant
activity planning ideas), labelling emotions, shifting your attention,
structured problem solving, managing upsetting mental images,
assertive communication, reassurance seeking frequently asked
questions (FAQs)
Worksheets (Extra resources):
Thought monitoring worksheet, behavioural experiment form,
thought challenging worksheet, pros and cons worksheet, activity
planning and monitoring worksheet.
74 J.M. Newby et al. / Internet Interventions 6 (2016) 71–79was recorded by the clinician in each participant's case notes, and
summed at the end of the study.
2.7. Measures
2.7.1. Diagnostic interviews
The Anxiety Disorders Interview Schedule for DSM-5 (ADIS-5) (Brown
and Barlow, 2014). TheADIS-5 is a semi-structured diagnostic interview
used to assess DSM-5 anxiety, depressive and somatic symptomdiagno-
ses. In the absence of any validated diagnostic interviews to assess the
new DSM-5 criteria for IAD and SSD at the start of the trial, we adminis-
tered the IAD and SSD modules of the ADIS-5.
Mini International Neuropsychiatric Interview Version 5.0.0 (Sheehan
et al., 1998). The MINI is a semi-structured diagnostic interview that
was employed to assess the presence of current comorbid Panic Disor-
der, Agoraphobia, GAD, OCD and MDD. The MINI possesses inter-rater
reliability ranging between k = 0.88.-1.00 and concurrent validity
with the Composite International Diagnostic Interview (CIDI, see
Kessler and Ustun, 2004).
2.7.2. Primary clinical outcomes
The Short Health Anxiety Inventory (SHAI) (Salkovskis et al., 2002).
The SHAI is a validated 18-item self-report measure of the severity of
health anxiety symptoms over the past week. The measure has good
psychometric properties including good internal consistency, test-
retest reliability and construct validity, and is sensitive to treatment
(Abramowitz et al., 2007; Alberts et al., 2013). Participants are asked
to rate each item with four response options to examine cognitive and
behavioural features of health anxiety. Items are rated on a four pointscale, ranging from 0–3 (for example, the ﬁrst item is: 0 = I do not
worry about my health, 1 = I occasionally worry about my health,
2 = I spend much of my time worrying about my health, and 3 = I
spendmost of my timeworrying about my health). In the current sam-
ple, the internal reliability estimate for the 18-item total score was 0.90.
2.7.3. Secondary clinical outcomes
Body Vigilance Scale Short-Form (BVS-SF) (Schmidt et al., 1997). The
BVS-SF is a 3-item self-report measure of body vigilance, or the con-
scious monitoring and attention of internal states. Participants are
instructed to rate over the past week (i) how much they paid close at-
tention to internal bodily sensations, and (ii) how sensitive they were
to changes in their internal bodily sensations (on a 1 = not at all, 5 =
moderately, and 10 = extremely scale), and (iii) how much time they
spent each day ‘scanning’ their body for sensations such as sweating,
heart palpitations, and dizziness (where 0 = none, 5 = half of the
time, and 10= all of the time). The BVS has been shown to be elevated
in patients with panic disorder, hypochondriasis and GAD, and has been
associated with health care utilisation and health-related safety behav-
iours (Olatunji et al., 2007). In the original version of the BVS, an addi-
tional item is used to assess how much attention the individual pays
to 15 symptoms of panic attacks, butwe did not administer this itembe-
cause our aim was to assess hypervigilance to bodily sensations more
generally (rather than panic-speciﬁc sensations). In the current sample
internal consistency of the 3-item measure was α= 0.88.
The Cognitions about Body and Health (CABAH) (Rief et al., 1998) is a
31-item self-report measure of dysfunctional cognitions and assump-
tions related to the body, health, and illness behaviour, including
catastrophising about minor bodily complaints. Participants rate their
1 The GAD-7, WHODAS, CABAH, IUS-12 and MAAS were not administered at mid-
treatment because we wanted to minimise the burden placed on participants from com-
pleting questionnaires during the treatment program.
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can be a sign of a beginning paralysis”) on a 4-point scale ranging
from 3 = completely right, 2 = mostly right, 1 = mostly wrong, and
0 = completely wrong. Internal consistency in the current study for
the total scale at pre-treatment α= 0.83.
The Generalised Anxiety Disorder 7-item scale (GAD-7, Spitzer et al.,
2006) measured generalised anxiety disorder symptoms (e.g., “Feeling
nervous, anxious, or on edge”) over the past fortnight on a scale ranging
from 0 (not at all) to 3 (nearly every day), where 1= several days, 2 =
more than half of the days. The scale has good reliability and validity
(0.85; Kroenke et al., 2007). In the current sample, internal consistency
was α= 0.83.
The Intolerance of Uncertainty Scale – 12-item Short-Form (IUS-12
Carleton, Norton & Asmundson, 2007) is a 12-item self-report measure
of intolerance of uncertainty. Participants rate the degree to which each
item is characteristic of them (e.g., I can't stand being taken by surprise)
on a scale from 1 (not at all) to 5 (entirely characteristic of me).
The Kessler 10-item Psychological Distress Scale (K-10; Kessler et al.,
2002) is a 10-item measure of non-speciﬁc psychological distress.
Items (e.g., “About how often did you feel nervous?”) are assessed on
a 5-point scale over the past fortnight. The K-10 has excellent psycho-
metric properties (Furukawa et al., 2003), and higher scores indicate
higher distress, with a score above 20 indicating clinical distress levels.
In the current sample, internal consistency was α= 0.90.
The Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 (Kroenke
et al., 2001) is a widely used 9-item measure of depression symptoms
experienced over the past 2 weeks. Participants rate the frequency of
symptoms (e.g., “Feeling down, depressed, or hopeless”) over the past
fortnight on a scale ranging from 0 (not at all) to 3 (nearly every day),
where 1 = several days, 2 = more than half of the days. The measure
has good internal consistency (α= 0.86–0.89), test-retest reliability
(r= 0.84 over 48 h), and construct validity (Kroenke et al., 2001). It is
also sensitive to change across CBT (Kroenke et al., 2001; Perini et al.,
2009). In the current sample, internal consistency was α= 0.78.
The Patient Health Questionnaire 15-item Scale (PHQ-15) (Kroenke
et al., 2002) is a 15-item scale of the severity of a range of somatic symp-
toms experienced over the past four weeks. Items (e.g., stomach pain,
back pain, headaches) are rated on a 3-point scale (where 0=not both-
ered at all, 1 = bothered a little, 2 = bothered a lot) over the past four
weeks. This measure has been demonstrated to have good internal con-
sistency (α= 0.80), (Gierk et al., 2015), and is predictive of functional
impairment, and health care utilisation in medical outpatient samples
(Kroenke et al., 2002). Scores of 5, 10 and 15 represent cut-off points
for low, medium and high severity of somatic symptoms. In the current
sample, internal consistency was α= 0.77 at baseline.
TheMindful Awareness and Attention Scale (MAAS) (Brown and Ryan,
2003) is a 15-item self-report measure of the core characteristic of trait
mindfulness (awareness of and attention to what is happening in the
presentmoment). Items (e.g., “I ﬁnd it difﬁcult to stay focused onwhat's
happening in the present”) are rated on a 7-point scale regarding the
degree to what each item reﬂects their experience ranging from 1 (al-
most always) to 6 (almost never). Higher scores indicate higher trait
or dispositional mindfulness. The MAAS has demonstrated to have
good internal consistency (0.80–0.90, and 0.83 in the current sample),
test-retest reliability, and discriminant validity (Brownand Ryan, 2003).
The 12-itemWorld Health Organisation Disability Assessment Schedule
(WHODAS -II). The WHODAS-II (Rehm et al., 1999) assesses functional
impairment and disability due to health conditions (including mental
or emotional difﬁculties) over the past month. Reliability (current
α= 0.83) and validity are sound (Andrews et al., 2009).
Worry Behaviours Inventory Short-Form (WBI-SF) (adapted from
Mahoney et al., 2016). TheWBI is a new self-report measure of safety be-
haviours and avoidant behaviours associated with worry. Five of the 6
items administered in the short-form were drawn from the original 20-
item WBI, with the 6th item added to assess body checking because of
its critical role in health anxiety. Participants are asked to rate thefrequency of 6 behaviours over the past week, including reassurance-
seeking, distraction, avoidance, reassurance-seeking through information
(e.g., internet searching), general checking, and body checking. While
there are no published psychometric evaluations of the short form,
Mahoney et al. (2016) provide evidence for internal reliability (α =
0.86), construct validity, and discriminant validity of the WBI. In the cur-
rent sample, internal consistency of theWBI-SFwasα=0.75 at baseline.
2.7.4. Acceptability ratings
2.7.4.1. Time spent reading lessons. To assess engagement in the program,
we asked participants how long they spent (in minutes) reading the
previous lesson and practicing the skills they had learnt.
2.7.4.2. Emotional reactions and unwanted side effects. After each lesson,
participants completed a 2-itemmeasure of their emotional and physi-
cal reactions to the lesson content. Theywere asked to compare: (i) how
anxious they felt after the lesson compared to how they felt before they
started reading the lesson on a 5-point scale (a lot less anxious/a little
bit less anxious/no change/a little more anxious/a lot more anxious),
and (ii) how intense their physical sensations felt after the lesson com-
pared to before (a lot less intense/a little less intense/no change/a little
bit more intense/a lot more intense). In addition, participants were
asked at post-treatment whether they had experienced any unwanted
side effects or negative events that occurred because of the program,
and were asked to provide brief details in an open text ﬁeld.
2.7.4.3. Treatment satisfaction questionnaire. At post-treatment, partici-
pants were asked to rate how satisﬁed they were with the program on
a 5-point scale ranging from 0= very dissatisﬁed to 5 = very satisﬁed.
They were also asked to rate the quality of the material in each lesson
and the quality of their contact with the clinical team (excellent/good/
satisfactory/unsatisfactory), as well as how they found the amount of
time (10 weeks) allocated to the entire program (much too little time/
a bit too little time/exactly the right amount of time/a bit too much
time). Finally, they were asked to rate how logical the program was,
their conﬁdence that the programwas successful in teaching them skills
to manage their anxiety, and their conﬁdence in recommending the
program to a friend with health anxiety, on a scale from 1–10 (where
1 = not very, and 10 = very).
2.8. Outcome measurement
All participants completed the SHAI, K-10, WBI-SF, and the BVS-SF
before they commenced each lesson, and these measures were also ad-
ministered at post-treatment and 3-month follow-up. The K-10 was
used as a measure to alert the clinician if participants' scores rose by
N0.5SD between lessons, indicating a signiﬁcant increase in distress, or
if their scores rose above 30 (severe range). The PHQ-9 and PHQ-15
were administered at pre-, mid- (before lesson 4), post-treatment and
3-month follow-up. The GAD-7, WHODAS, CABAH, IUS-12 and MAAS
were administered at baseline, post-treatment and 3-month follow-
up.1
2.9. Power calculation
We used G*Power to conduct a power calculation and determine
sample size (Faul et al., 2007): a sample size of n = 10 was needed to
detect a large within-group (pre to post) effect size of d = 1.0 at 80%
power, alpha set at 0.05 (two-tailed).
2 Due to a technical issue (browser incompatibility) with the administration of this
questionnaire, the questionnaire was not administered to all participants.
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All analyses were implemented in SPSS v. 22. To investigate reduc-
tions in the primary and secondary outcome measures from pre- to
post-treatment, and from pre-treatment to 3-month follow-up, a linear
mixedmodel for each of the outcomemeasureswas implemented using
the MIXED procedure with a random intercept for subject. Mixed
models estimate parameters in repeated measures studies with unbal-
anced data using maximum likelihood estimation. This makes use of
the incomplete data in away that does not bias the parameter estimates
(West et al., 2006). For each outcome, time was treated as a categorical
variable, and an identity covariance structure was speciﬁed to model
the covariance structure of the random intercept. Initial model building
focused on the selection of the most appropriate covariance structure
for the residual correlation matrix. Model ﬁt indices and inspection of
the variance-covariance matrix supported the selection of the identity
covariance structure for each of the outcome measures. Effect sizes
(Hedges g, adjusted for sample size) were calculated to determine the
size of the within-group reduction between pre-treatment to post-
treatment, and pre-treatment to 3-month follow-up. Finally, based on
Jacobson andTruax (1991), reliable change (RCI) valueswere calculated
for SHAI scores to determine the proportion of participants who evi-
denced clinically reliable improvements between baseline and post-
treatment. We used test-retest reliability estimates of 0.87 from
Olatunji et al. (2011), and SD of 7.24 derived from the current sample
to calculate these values.
3. Results
3.1. Participant characteristics
Participants (N = 16, 81% females) were adults (mean age: 41.4
years, SD = 16.27, range = 19–69) with a DSM-5 diagnosis of either
IAD (n = 10, 62.5%) or SSD (n = 6, 37.5%). Participants met criteria
for an average of 2 diagnoses (range = 1–4 diagnoses, SD = 0.89);
three participants met criteria for MDD (18.8%), 5 had GAD (31.3%), 4
had panic disorder (25%), three had agoraphobia (18.8%), and one had
OCD (6.3%). The mean score on the SHAI was 32.94 (SD = 7.64,
range = 22–45), which is in the clinical range (Alberts et al., 2013).
One participant was receiving concurrent psychological treatment
(CBT), and two were taking medications for anxiety or depression
(both were on selective serotonin reuptake inhibitors).
Themajority of the samplewere eithermarried or living in a de facto
relationship (n = 11, 68.8%), 4 were single/never married (25%), and
one participant was divorced (6.3%). Thirteen participants (81.3%)
were in paid employment, twowere retired (12.5%), and onewas regis-
tered sick/disabled (6.3%). All reported that English was the main lan-
guage spoken at home. The majority were born in Australia (n = 10,
62.5%), with the remaining participants from England (n= 4, 25%), or
other European countries (n = 2, 12.6%). In terms of education, 9 had
attained tertiary level education (56.3%), 4 participants completed
year 12 or equivalent (25%), and the remaining either had no qualiﬁca-
tion (n = 1, 6.3%), or other certiﬁcate/diploma level education (n = 2,
12.6%).
Participants found out about the program from a variety of sources
including social media (n= 6, 37.6%), frommental health professionals
or general practitioners (n=3, 18.9%), internet searches (n=3, 18.9%),
word of mouth (n = 2, 12.6%), or other sources (n = 1, 6.3%).
3.2. Adherence
Of the 16 participants who started the program, 13 participants
completed all 6 lessons of the program (81.25% completion rate). Of
the non-completers, one participant withdrew from the program after
completing two lessons to seek face-to-face treatment. The remaining
two participants completed two lessons each.3.3. Primary and secondary outcomes at post-treatment
Table 2 includes the estimatedmarginal means and the linearmixed
model results for each of the outcome measures at pre- and post-
treatment, and at 3-month follow-up. For all outcomemeasures, the re-
duction in symptoms from pre- to post-treatment was statistically sig-
niﬁcant at the p b 0.001 level, except for IUS-12 scores which were
signiﬁcant at the p b 0.01 level. Table 2 also reports the effect sizes of
the pre-to post-treatment changes on outcome measures. Effect sizes
were moderate for CABAH scores (g = 0.78), and the remaining effect
sizes were large (Hedges gs = 1.04–1.67).
3.4. Proportion of participants who achieved clinically reliable change in
health anxiety
Twelve out of the fourteen participants with post-treatment data
(86%) showed clinically reliable improvements on SHAI scores between
baseline and post-treatment.
3.5. Primary and secondary clinical outcomes at 3-month follow-up
For all outcome measures, the reduction in symptoms from pre-
treatment to 3-month follow-up was statistically signiﬁcant at the
p b 0.001 level, except for IUS-12 scores which were signiﬁcant at the
p b 0.05 level. Pre-treatment to follow-up effect sizes were large for all
variables (Hedges gs = 0.84–1.65).
3.6. Clinician contact
The clinician (JN) spent an average of 27 min (SD= 11.7, range =
15–59) emailing and calling each participant in the iCBT group during
the treatment course (including the follow-up period).
3.7. Participants' engagement with program
On average, the participants spent between 39 to 55 min reading
each lesson, and between 60–112 min practicing the skills. However,
there was a large degree of variability in the self-reported time spent
on the program, with the time spent ranging from 2 to 220min reading
(and re-reading) the lessons, and between 0 and 300min practicing the
skills.
3.8. Emotional reactions to the lessons
There were only three instances of reported mild increases in anxi-
ety, and three instances of reported mild increases in the intensity of
physical sensations after reading the program lessons. Of those who re-
ported increased anxiety after the lessons, only two participants report-
ed feeling a “little more” anxious and “a little more intense physical
sensations” after reading lesson 1 (13.3%), and one participant felt a “lit-
tle more anxious” and “a little more intense physical sensations” after
lesson 3 (10%). In contrast, the majority of participants reported feeling
less anxious after reading the lessons (lesson 1: n=9/15, 60%; lesson 2:
n=5/12, 41.7%; lesson 3: 7/10, n=70%; lesson 4: 6/10, n=60%; lesson
5: 4/11, 36.4%; lesson 6: n = 7/10, 70%).2
3.9. Treatment satisfaction
Of the 14 participants who completed the post-treatment question-
naires, all participants reported that they were either mostly (n = 8,
57.1%) or very (n = 6, 42.9%) satisﬁed with the program, and rated
the quality of both the lesson content and contact with the clinical
team as either good or excellent (lesson content: good: n = 7, 50%,
Table 2
Estimated marginal means at pre-, mid- post-treatment and 3 months following internet CBT for health anxiety.
Pre-treatment Mid-treatment Post-treatment 3-month
follow-up
Pre- to post-treatment Pre-treatment to follow-up
Mean (SD)
n = 16
Mean (SD)
n = 13
Mean (SD)
n = 13
Mean (SD)
n = 11
F(df) r Effect size: Hedges
g (95% CI)
F(df) R Effect size:
Hedges g
(95% CI)
Symptoms
Health Anxiety (SHAI) 32.94 (7.24) 23.67 (7.10) 18.70 (6.89) 18.01 (6.77) F (2, 26.35) =
25.44⁎⁎
0.31 1.64 (0.80–2.49) F (3, 37.61) =
24.41⁎⁎
0.42 1.60
(0.73–2.48)
Distress (K−10) 26.19 (6.00) 16.86 (5.99) 15.83 (5.99) 16.01 (5.27) F (2, 76.46) =
18.27⁎⁎
0.004 1.67 (0.82–2.52) F (3, 37.15) =
17.06⁎⁎
0.40 1.36
(0.51–2.21)
Depression (PHQ-9) 8.31 (3.36) 3.71 (3.35) 3.36 (3.24) 2.30 (2.98) F (2, 25.69) =
14.38⁎⁎
0.35 1.20 (0.40–1.99) F (3, 37.02) =
13.75⁎⁎
0.27 1.35
(0.50–2.20)
Somatic Symptoms
(PHQ-15)
13.56 (4.76) 8.71 (4.40) 7.88 (4.36) 7.53 (4.11) F (2, 24.27) =
39.31⁎⁎
0.73 1.27 (0.48–2.08) F (3, 35.04) =
27.18⁎⁎
0.66 1.30
(0.45–2.14)
Generalised Anxiety
(GAD-7)
10.81 (4.04) – 4.78 (3.97) 4.62 (3.78) F (1, 12.25) =
25.09⁎⁎
0.40 1.52 (0.69–2.35) F (2, 23.98) =
16.89⁎⁎
0.38 1.27
(0.47–2.07)
Disability (WHODAS) 20.25 (4.76) – 14.72 (4.72) 13.35 (3.91) F (1, 9.72) =
16.25⁎
0.38 1.24 (0.45–2.04) F (2, 18.21) =
19.30⁎⁎
0.58 1.12
(0.33–1.90)
Cognitive and behavioural processes:
Worry Behaviours
(WBI-SF)
12.31 (3.88) 6.90 (3.89) 6.63 (3.75) 3.86 (3.52) F (2, 24.85) =
13.27⁎⁎
0.47 1.04 (0.26–1.82) F (3, 36.39) =
16.31⁎⁎
0.08 1.65
(0.77–2.54)
Body Vigilance (BVS-SF) 21.31 (6.04) 11.67 (6.04) 10.90 (5.80) 11.17 (5.97) F (2, 27.79) =
17.76⁎⁎
0.22 1.46 (0.64–2.28) F (3, 39.48) =
12.28⁎⁎
0.29 1.26
(0.42–2.10)
Cognitions
(CABAH)
45.50 (8.96) – 37.84 (8.29) 31.42 (8.99) F (1, 12.45) =
40.03⁎⁎
0.90 0.78 (0.03–1.54) F (2, 24.40) =
23.64⁎⁎
0.71 1.03
(0.25–1.81
Intolerance of Uncertainty
(IUS-12)
35.69 (9.88) – 25.71 (9.84) 25.17
(10.81)
F (1, 13.60) =
9.53⁎
0.26 1.04 (0.26–1.82) F (2, 26.25) =
5.10#
0.09 0.84
(0.08–1.61)
Mindful Awareness and
Attention (MAAS)
50.94 (9.52) – 61.24 (9.12) 63.27 (8.89) F (1, 12.50) =
24.82⁎⁎
0.67 1.12 (0.34–1.91) F (2, 23.92) =
18.84⁎⁎
0.62 1.05
(0.27–1.83)
⁎⁎ p b 0.001 ⁎ p b 0.01 # p b 0.05.
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n = 9, 64.3%). In terms of the tempo of the program (the scope of the
program in relation to its length), more than half felt they had too little
time (n = 9, 64.3%), two thought it was too much time (14.3%), and
three felt it was the right amount of time (21.4%).
Overall, participants rated the program as logical (M= 8.36, SD=
1.69), endorsed high levels of conﬁdence in having the techniques to
manage health anxiety (M = 7.5, SD = 1.40), and conﬁdence in
recommending the iCBT course to a friend with health anxiety (where
1 = not at all and 10 = very) (M= 8.5, SD= 1.09).
3.10. Side effects
Of 14 participants who completed the questionnaire, 8 did not re-
port any side effects, leaving 6 who reported experiencing unwanted
side effects as a result of the program. One participant for example re-
ported increased anxiety at the start of the program (Participant
Quote: “I think I went through a phase where I was more anxious than
ever because of things that the program brought up but I didn't yet have
the tools to cope with them. The ﬁrst few weeks were very tough.”).
Three reported ‘setbacks’ in response to graded exposure (Participant
Quote: “I did have a very bad week, partly related to the commencement
of graded exposure but also to the onset of a new ‘symptom’. It certainly
gave me an opportunity to practice!” Participant Quote:“The effects of
the materials in lesson 5 that encouraged participants to exposure to the
source of fear: I was uncomfortable with some of my reactions…” Partici-
pant Quote: “Had a signiﬁcant backslide – possibly owing to the exposure
that I wasn't ready for. Conversations with the clinician at this point were
particularly useful, however”). There was also one participant who re-
ported thinking about their health more (“There were times when I was
thinking about health things more and the fact I was running behind on
my lessons mademe feelmore anxious, but nothing dramatic or ongoing.”).
Finally, the remaining participant reported a non-speciﬁc set back (“I've
had a setback but it wasn't unwanted: I used the skills I had learned and got
through it, and I'll get through any other setbacks I may have in the course
of my life.”).4. Discussion
This study aimed to explore the acceptability of an internet CBT pro-
gram for the treatment of health anxiety, and its impact onhealth anxiety,
comorbid symptoms and key cognitive and behavioural maintaining fac-
tors including illness-related cognitions, hypervigilance to bodily sensa-
tions, and avoidance and safety behaviours (e.g., checking, reassurance-
seeking and internet searching). In a sample of 16 individuals who met
criteria for DSM-5 Illness Anxiety Disorder or Somatic SymptomDisorder,
we found large and signiﬁcant reductions between baseline and post-
treatment on measures on health anxiety (g = 1.64), depression (g =
1.20), distress (g = 1.67), generalised anxiety (g = 1.57), disability (g
= 1.24), and somatic symptom severity (g = 1.27), which were main-
tained until 3 months following the program. The majority of partici-
pants (86%) experienced clinically reliable met improvements in
health anxiety scores between baseline and post-treatment (Jacobson
and Truax, 1991). As predicted, most participants completed the iCBT
program (adherence = 81%), and treatment satisfaction ratings were
high.
These positive results were observed with minimal clinician input,
with the clinician spending on average 27 min per participant. While
most of the previous evaluations of iCBT for health anxiety have in-
volved weekly support from a therapist (e.g., Hedman et al., 2011),
our results support those of Hedman and colleagues (Hedman et al.,
2016) who showed that both unguided iCBT and therapist-guided
iCBT (as well as CBT-based bibliotherapy for health anxiety) produce
large and positive reductions in health anxiety. Together, these studies
suggest that iCBT can improve symptoms of health anxiety with rela-
tively minimal clinician contact time.
Our results also showed that the iCBT program led to improvements
on the key cognitive and behavioural maintaining factors that are
hypothesised to maintain health anxiety according to existing theoreti-
cal models of the condition (Warwick, 1989). We found signiﬁcant
reductions in dysfunctional health-related cognitions, behaviours (in-
cluding reassurance-seeking, avoidance and internet searching) and
body vigilance, aswell as increases inmindful awareness and the ability
78 J.M. Newby et al. / Internet Interventions 6 (2016) 71–79to tolerate uncertainty. Because of the small sample size, we were un-
able to assess the mechanism by which iCBT produced symptom
improvements. Future studies should include mediation analyses to
examine whether changes in important theoretical constructs
(e.g., intolerance of uncertainty, hypervigilance to bodily sensations)
mediate reductions in health anxiety. Preliminary evidence from
Hedman et al. suggested that reductions in perceptions of risk of dis-
ease, intolerance of uncertainty and body hypervigilance may mediate
improvements in health anxiety symptoms during iCBT (Hedman
et al., 2013a), but this ﬁnding is yet to be replicated. It is also currently
unknown whether changes in maladaptive behaviours such as reduc-
tions in body checking, reassurance-seeking or internet searchingmedi-
ate symptom improvements during iCBT.
This study assessed unwanted side effects or negative reactions to
internet CBT for health anxiety, which is in line with calls for increased
assessment of unwanted side effects of internet interventions (Rozental
et al., 2014). Hedman and colleagues have previously collected data on
adverse events via self-report questionnaire at post-treatment, and
found adverse events were reported by a small minority of individuals
undergoing therapist-supported iCBT (19% in Hedman et al., 2016;
12% in Hedman et al., 2014) with the most common being an increase
in anxiety. In the current study, we collected information about un-
wanted reactions to iCBT after each lesson and at post-treatment.
Despite the potential for health-related information to trigger fears
of illness and amplify the perceived intensity of somatic symptoms in
health anxious individuals, the majority of participants said that they
felt less anxious and less intense physical sensations as a direct result
of completing the lessons. It is possible that these ﬁndings are a reﬂec-
tion of the distraction afforded by reading the lessons, which may
have in turn reduced body vigilance, and therefore reduced anxiety. In-
terestingly, instances of increased anxietywhilst completing the lessons
were less common, and only reported to bemild. However, 6 of 14 indi-
viduals who completed post-treatment assessments reported some
unwanted negative effects of the program, with the most common re-
ported including setbacks after starting exposure; most used the un-
wanted side effects as an opportunity to practice their new skills.
Future research should focus on examining the nature of unwanted
side effects of iCBT for health anxiety in larger samples, how patients
perceive these side effects in balance of the ‘wanted side effects’ or im-
provements they typically experience as a result of iCBT, and explore
whether the experience of side effects predicts drop-out, or inﬂuences
outcomes.
The results of this pilot trial need to be interpreted in the context of
some limitations. The small sample size precluded a thorough analysis
of predictors of treatment adherence and outcome. In future, it would
be useful to examine whether there are any important differences in
treatment response between individuals with DSM-5 IAD versus SSD,
and whether patients who experience health anxiety in the context of
diagnosed medical illnesses (e.g., cancer survivors who fear cancer
recurrence) or physical pathology, respond as well to iCBT as those
without diagnosed illnesses and/or medically unexplained symptoms.
Hedman et al. (2013b) found that higher baseline health anxiety pre-
dicted larger improvements in health anxiety, although higher baseline
depression predicted a poorer response to iCBT for health anxiety. These
latter ﬁndings are in line with a meta-analysis showing that comorbid
depressionmaymoderate the effects of CBT, with higher depression as-
sociated with smaller effect sizes (Olatunji et al., 2014). Our sample was
too small (with only three individuals meeting criteria for MDD) to de-
termine whether comorbid depression predicted outcomes. Future
RCTs are needed to examine this issue, and to compare the Health Anx-
iety Program to control groups to rule out the inﬂuence of other non-
speciﬁc factors in the improvements in symptoms observed in this sam-
ple (e.g., non-speciﬁc treatment factors, assessment and clinician
support).
Furthermore, we did not conduct inter-rater reliability estimates for
the diagnoses made in the current study. Although themean ratings onthe self-report questionnaires attest to the clinical nature of the sample,
future studies are needed to determine the inter-rater reliability of the
IAD and SSD diagnoses using the ADIS-5 interview. Although Axelsson
and colleagues foundevidence of the reliability of theHealth Preoccupa-
tion Interview (anew structured interview for DSM-5 IAD and SSDdiag-
noses, yielding inter-rater agreement of 0.85) in diagnosing IAD and
SSD, this ﬁnding is yet to be replicated, and the inter-rater reliability
of the IAD and SSDmodules of the ADIS-5 is not yet known. The assess-
ment of treatment outcomes also relied on self-report data. While such
outcome measures are valid and widely used, additional measures re-
lated to objective reductions in health care utilisation, as well as diag-
nostic status and clinician severity ratings would have augmented the
current ﬁndings. Finally, the representativeness of the sample who re-
ceived iCBT to the general population of individuals with health anxiety
is not yet known.
In summary, the results of this pilot trial show that internet CBT for
health anxiety is acceptable, and yields large and signiﬁcant improve-
ments on health anxiety and comorbid symptoms. This program now
needs to be evaluated in a RCT with long-term follow-up to evaluate
the efﬁcacy of the program, and how long the symptom improvements
are maintained.Acknowledgements
Funding for this study was provided by the National Health and
Medical Research Council of Australia (NHMRC) in the form of an
Early Career Fellowship awarded to Dr. Jill Newby (NHMRC grant num-
ber 1037787).References
Abramowitz, J.S., Braddock, A.E., 2011. Hypochondriasis and Health Anxiety. Hogrefe,
Cambridge, MA.
Abramowitz, J., Deacon, B., Valentiner, D., 2007. The short health anxiety inventory: psy-
chometric properties and construct validity in a non-clinical sample. Cogn. Ther. Res.
31 (6), 871–883. http://dx.doi.org/10.1007/s10608-006-9058-1.
Alberts, N.M., Hadjistavropoulos, H.D., Jones, S.L., Sharpe, D., 2013. The short health anxi-
ety inventory: a systematic review and meta-analysis. J. Anxiety Disord. 27 (1),
68–78. http://dx.doi.org/10.1016/j.janxdis.2012.10.009.
American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Dis-
orders. Fifth edition. American Psychiatric Association, Arlington, VA.
Anderson, R., Saulsman, L., Nathan, P., 2011. Helping Health Anxiety. Centre for Clinical In-
terventions, Perth, Western Australia.
Andrews, G., Kemp, A., Sunderland, M., Von Korff, M., Ustun, T.B., 2009. Normative data for
the 12 itemWHODisability Assessment Schedule 2.0. PLoS ONE 4 (12), e8343. http://
dx.doi.org/10.1371/journal.pone.0008343.
Andrews, G., Cuijpers, P., Craske, M.G., McEvoy, P., Titov, N., 2010. Computer therapy for
the anxiety and depressive disorders is effective, acceptable and practical health
care: a meta-analysis. PLoS One 5 (10).
Barsky, A.J., Wyshak, G., Klerman, G.L., 1990. The somatosensory ampliﬁcation scale and
its relationship to hypochondriasis. J. Psychiatr. Res. 24 (4), 323–334.
Bobevski, I., Clarke, D.M., Meadows, G., 2016. Health anxiety and its relationship to dis-
ability and service use: ﬁndings from a large epidemiological survey. Psychosom.
Med. 78 (1), 13–25.
Brown, T.A., Barlow, D., 2014. Anxiety and Related Disorders Interview Schedule for DSM-
5 (ADIS-5). Oxford University Press, New York.
Brown, K.W., Ryan, R.M., 2003. The beneﬁts of being present: mindfulness and its role in
psychological well-being. J. Pers. Soc. Psychol. 84 (4), 822–848. http://dx.doi.org/10.
1037/0022-3514.84.4.822.
Carleton, R.N., Norton, M.A., Asmundson, G.J.G., 2007. Fearing the unknown: A short ver-
sion of the intolerance of uncertainty scale. J. Anxiety Disord. 21, 105–117 doi: S0887-
6185(06)00051-X [pii]10.1016/j.janxdis.2006.03.014.
Conradt, M., Cavanagh, M., Franklin, J., Rief, W., 2006. Dimensionality of the Whiteley
Index: Assessment of hypochondriasis in an Australian sample of primary care pa-
tients. J. Psychosom. Res. 60 (2), 137–143. http://dx.doi.org/10.1016/j.jpsychores.
2005.07.003.
Creed, F., Barsky, A., 2004. A systematic review of the epidemiology of somatisation disor-
der and hypochondriasis. J. Psychosom. Res. 56 (4), 391–408. http://dx.doi.org/10.
1016/s0022-3999(03)00622-6.
Faul, F., Erdfelder, E., Lang, A.G., Buchner, A., 2007. G*Power 3: a ﬂexible statistical power
analysis program for the social, behavioral, and biomedical sciences. Behav. Res.
Methods 39 (2), 175–191.
Ferguson, E., Swairbrick, R., Clare, S., Robinson, E., Bignell, C.J., Anderson, C., 2000. Hypo-
chondriacal concerns, somatosensory ampliﬁcation, and primary and secondary cog-
nitive appraisals. Br. J. Med. Psychol. 73 (Pt 3), 355–369.
79J.M. Newby et al. / Internet Interventions 6 (2016) 71–79Fink, P., Ørnbøl, E., Christensen, K.S., 2010. The outcome of health anxiety in primary care:
A two-year follow-up study on health care costs and self-rated health. PLoS One 5
(3). http://dx.doi.org/10.1371/journal.pone.0009873.
Furer, P., Walker, J.R., Stein, M.B., 2007. Treating Health Anxiety and Fear of Death: A
Practitioner's Guide. Springer, New York.
Furukawa, T., Kessler, R., Slade, T., Andrews, G., 2003. The performance of the K6 and K10
screening scales for psychological distress in the Australian National Survey ofMental
Health and Well-Being. Psychol. Med. J. Res. Psychiatry Allied Sci. 33 (2), 357–362.
Gierk, B., Kohlmann, S., Toussaint, A., Wahl, I., Brunahl, C.A., Murray, A.M., Lowe, B., 2015.
Assessing somatic symptom burden: a psychometric comparison of the patient health
questionnaire-15 (PHQ-15) and the somatic symptom scale-8 (SSS-8). J. Psychosom.
Res. 78 (4), 352–355. http://dx.doi.org/10.1016/j.jpsychores.2014.11.006.
Gureje, O., Üstün, T.B., Simon, G.E., 1997. The syndrome of hypochondriasis: a cross-
national study in primary care. Psychol. Med. J. Res. Psychiatry Allied Sci. 27 (5),
1001–1010. http://dx.doi.org/10.1017/s0033291797005345.
Hedman, E., Andersson, G., Andersson, E., Ljotsson, B., Ruck, C., Asmundson, G.J., Lindefors,
N., 2011. Internet-based cognitive-behavioural therapy for severe health anxiety:
randomised controlled trial. Br. J. Psychiatry 198 (3), 230–236.
Hedman, E., Ljotsson, B., Lindefors, N., 2012. Cognitive behavior therapy via the internet: a
systematic review of applications, clinical efﬁcacy and cost-effectiveness. Expert Rev.
Pharmacoecon. Outcomes Res. 12 (6), 745–764. http://dx.doi.org/10.1586/erp.12.67.
Hedman, E., Andersson, E., Andersson, G., Lindefors, N., Lekander, M., Rück, C., Ljótsson, B.,
2013a. Mediators in internet-based cognitive behavior therapy for severe health anx-
iety. PLoS One 8 (10), e77752. http://dx.doi.org/10.1371/journal.pone.0077752.
Hedman, E., Lindefors, N., Andersson, G., Andersson, E., Lekander, M., Ruck, C., Ljotsson, B.,
2013b. Predictors of outcome in internet-based cognitive behavior therapy for severe
health anxiety. Behav. Res. Ther. 51 (10), 711–717. http://dx.doi.org/10.1016/j.brat.
2013.07.009.
Hedman, E., Andersson, E., Lindefors, N., Andersson, G., Ruck, C., Ljotsson, B., 2013c. Cost-
effectiveness and long-term effectiveness of internet-based cognitive behaviour ther-
apy for severe health anxiety. Psychol. Med. 43 (2), 363–374.
Hedman, E., Axelsson, E., Gorling, A., Ritzman, C., Ronnheden, M., El Alaoui, S., ... Ljotsson,
B., 2014. Internet-delivered exposure-based cognitive-behavioural therapy and be-
havioural stress management for severe health anxiety: randomised controlled
trial. Br. J. Psychiatry 205 (4), 307–314. http://dx.doi.org/10.1192/bjp.bp.113.140913.
Hedman, E., Axelsson, E., Andersson, E., Lekander, M., Ljótsson, B., 2016. Exposure-based
cognitive–behavioural therapy via the internet and as bibliotherapy for somatic
symptom disorder and illness anxiety disorder: randomised controlled trial. Br.
J. Psychiatry http://dx.doi.org/10.1192/bjp.bp.116.181396.
Jacobson, N.S., Truax, P., 1991. Clinical signiﬁcance: a statistical approach to deﬁning
meaningul change in psychotherapy research. J. Consult. Clin. Psychol. 59 (1),
12–19. http://dx.doi.org/10.1037/0022-006X.59.1.12.
Kessler, R.C., Ustun, T.B., 2004. The world mental health (WMH) survey initiative version
of the World Health Organization (WHO) composite international diagnostic inter-
view (CIDI). Int. J. Methods Psychiatr. Res. 13 (2), 93–121.
Kessler, R., Andrews, G., Colpe, L., Hiripi, E., Mroczek, D., Normand, S., ... Zaslavsky, A.,
2002. Short screening scales to monitor population prevalences and trends in non-
speciﬁc psychological distress. Psychol. Med. J. Res. Psychiatry Allied Sci. 32 (6),
959–976.
Kroenke, K., Spitzer, R., Williams, J., 2001. The PHQ-9: validity of a brief depression sever-
ity measure. J. Gen. Intern. Med. 16 (9), 606–613. http://dx.doi.org/10.1046/j.1525-
1497.2001.016009606.x.
Kroenke, K., Spitzer, R.L., Williams, J.B., 2002. The PHQ-15: validity of a new measure for
evaluating the severity of somatic symptoms. Psychosom. Med. 64 (2), 258–266.
Kroenke, K., Spitzer, R.L., Williams, J.B.W., Monahan, P.O., Löwe, B., 2007. Anxiety disor-
ders in primary care: prevalence, impairment, comorbidity, and detection. Ann. In-
tern. Med. 146 (5), 317–325.
Mahoney, A.E., Mackenzie, A., Williams, A.D., Smith, J., Andrews, G., 2014. Internet cognitive
behavioural treatment for obsessive compulsive disorder: a randomised controlled trial.
Behav. Res. Ther. 63c, 99–106. http://dx.doi.org/10.1016/j.brat.2014.09.012.
Mahoney, A.E., Hobbs, M.J., Newby, J.M., Williams, A.D., Sunderland, M., Andrews, G.,
2016. The worry behaviors inventory: assessing the behavioral avoidance associated
with generalized anxiety disorder. J. Affect. Disord. 203, 256–264. http://dx.doi.org/
10.1016/j.jad.2016.06.020.
Newby, J.M., Mackenzie, A., Williams, A.D., McIntyre, K., Watts, S., Wong, N., Andrews, G.,
2013. Internet cognitive behavioural therapy for mixed anxiety and depression: a
randomized controlled trial and evidence of effectiveness in primary care. Psychol.
Med. 1–14 http://dx.doi.org/10.1017/s0033291713000111.
Newby, J.M., Mewton, L., Williams, A.D., Andrews, G., 2014. Effectiveness of transdiagnostic
internet cognitive behavioural treatment for mixed anxiety and depression in primary
care. J. Affect. Disord. 165, 45–52. http://dx.doi.org/10.1016/j.jad.2014.04.037.Olatunji, B.O., Deacon, B.J., Abramowitz, J.S., Valentiner, D.P., 2007. Body vigilance in non-
clinical and anxiety disorder samples: structure, correlates, and prediction of health
concerns. Behav. Ther. 38 (4), 392–401. http://dx.doi.org/10.1016/j.beth.2006.09.002.
Olatunji, B.O., Etzel, E.N., Tomarken, A.J., Ciesielski, B.G., Deacon, B., 2011. The effects of
safety behaviors on health anxiety: an experimental investigation. Behav. Res. Ther.
49 (11), 719–728. http://dx.doi.org/10.1016/j.brat.2011.07.008.
Olatunji, B.O., Kauffman, B.Y., Meltzer, S., Davis, M.L., Smits, J.A.J., Powers, M.B., 2014.
Cognitive-behavioral therapy for hypochondriasis/health anxiety: A meta-analysis
of treatment outcome and moderators. Behav. Res. Ther. 58 (0), 65–74. http://dx.
doi.org/10.1016/j.brat.2014.05.002.
Patel, S., Kai, J., Atha, C., Avery, A., Guo, B., James, M., ... Morriss, R., 2015. Clinical charac-
teristics of persistent frequent attenders in primary care: case-control study. Fam.
Pract. 32 (6), 624–630. http://dx.doi.org/10.1093/fampra/cmv076.
Perini, S., Titov, N., Andrews, G., 2009. Clinician-assisted internet-based treatment is effec-
tive for depression: randomized controlled trial. Aust. N. Z. J. Psychiatry 43 (6),
571–578. http://dx.doi.org/10.1080/00048670902873722.
Rehm, J., Ustun, B., Saxena, S., Nelson, C.B., Chatterji, S., Ivis, F., et al., 1999. On the devel-
opment and psychometric testing of the WHO screening instrument to assess dis-
ablement in the general population. Int. J. Methods Psychiatr. Res. 8, 110–122.
Rief, W., Hiller, W., Margraf, J., 1998. Cognitive aspects of hypochondriasis and the soma-
tization syndrome. J. Abnorm. Psychol. 107 (4), 587–595.
Rozental, A., Andersson, G., Boettcher, J., Ebert, D.D., Cuijpers, P., Knaevelsrud, C., ...
Carlbring, P., 2014. Consensus statement on deﬁning and measuring negative effects
of internet interventions. Internet Interv. 1 (1), 12–19. http://dx.doi.org/10.1016/j.
invent.2014.02.001.
Salkovskis, P., Rimes, K., Warwick, H., Clark, D., 2002. The health anxiety inventory: develop-
ment and validation of scales for the measurement of health anxiety and hypochondri-
asis. Psychol. Med. 32 (05), 843–853. http://dx.doi.org/10.1017/S0033291702005822.
Schmidt, N.B., Lerew, D.R., Trakowski, J.H., 1997. Body vigilance in panic disorder: evalu-
ating attention to bodily perturbations. J. Consult. Clin. Psychol. 65 (2), 214–220.
Seivewright, H., Green, J., Salkovskis, P., Barrett, B., Nur, U., Tyrer, P., 2008. Cognitive-
behavioural therapy for health anxiety in a genitourinary medicine clinic:
randomised controlled trial. Br. J. Psychiatry 193 (4), 332–337. http://dx.doi.org/10.
1192/bjp.bp.108.052936.
Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., ... Dunbar,
G.C., 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I): The develop-
ment and validation of a structured diagnostic psychiatric interview for DSM-IV and
ICD-10. J. Clin. Psychiatry 59 (Suppl. 20), 22–33.
Sorensen, P., Birket-Smith, M., Wattar, U., Buemann, I., Salkovskis, P., 2011. A randomized
clinical trial of cognitive behavioural therapy versus short-term psychodynamic psy-
chotherapy versus no intervention for patients with hypochondriasis. Psychol. Med.
41 (2), 431–441.
Spitzer, R.L., Kroenke, K., Williams, J.B., Lowe, B., 2006. A brief measure for assessing gen-
eralized anxiety disorder: The GAD-7. Arch. Intern. Med. 166 (10), 1092–1097.
Sunderland, M., Newby, J.M., Andrews, G., 2012. Health anxiety in Australia: prevalence,
comorbidity, disability and service use. Br. J. Psychiatry http://dx.doi.org/10.1192/
bjp.bp.111.103960.
Sunderland, M., Newby, J.M., Andrews, G., 2013. Health anxiety in Australia: prevalence,
comorbidity, disability and service use. Br. J. Psychiatry 202 (1), 56–61. http://dx.
doi.org/10.1192/bjp.bp.111.103960.
Thomson, A.B., Page, L.A., 2007. Psychotherapies for hypochondriasis. Cochrane Database
Syst. Rev. 4, CD006520. http://dx.doi.org/10.1002/14651858.CD006520.pub2.
Tyrer, P., Cooper, S., Salkovskis, P., Tyrer, H., Crawford, M., Byford, S., ... Barrett, B., 2013.
Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in
medical patients: a multicentre randomised controlled trial. Lancet.
Tyrer, P., Eilenberg, T., Fink, P., Hedman, E., Tyrer, H., 2016. Health anxiety: the silent, dis-
abling epidemic. BMJ 353. http://dx.doi.org/10.1136/bmj.i2250.
Walker, J., Vincent, N., Furer, P., Cox, B., Kjernisted, K., 1999. Treatment preference in hy-
pochondriasis. J. Behav. Ther. Exp. Psychiatry 30 (4), 251–258.
Warwick, H.M., 1989. A cognitive-behavioural approach to hypochondriasis and
health anxiety. J. Psychosom. Res. 33 (6), 705–711. http://dx.doi.org/10.1016/
0022-3999(89)90086-X.
Warwick, H.M., Salkovskis, P.M., 1990. Hypochondriasis. Behav. Res. Ther. 28 (2),
105–117. http://dx.doi.org/10.1016/0005-7967(90)90023-c.
Warwick, H.M.C., Clark, D.M., Cobb, A.M., Salkovskis, P.M., 1996. A controlled trail of
cognitive-behavioural treatment of hypochondriasis. Br. J. Psychiatry 169 (2),
189–195. http://dx.doi.org/10.1192/bjp.169.2.189.
West, B., Welch, K.B., Galecki, A.T., 2006. Linear Mixed Models: A Practical Guide Using
Statistical Software. Chapman & Hall/CRC.
